Cephalon, Inc.

89Bio, Inc.

Ignyta, Inc.

Kyowa Hakko Kogyo Co., Ltd.

Cancer Research Technology Limited

Other

Pharmacopeia Inc.

Teva Sante

Robert L Hudkins

Allison L Zulli

Nadine C Becknell

Reddeppa Reddy Dandu

Craig A Zificsak

Bruce D Dorsey

Ming Tao

Rabindranath Tripathy

Diane E Gingrich

Kurt A Josef

Linda Weinberg

Theodore L Underiner

Dimitar B Gotchev

Derek D Dunn

Edward R Bacon

Sankar Chatterjee

Catherine P Prouty

James L Diebold

Dandu R Reddy

John P Mallamo

Greg A Hostetler

Ernest Knight, Jr

Babu G Sundar

Thomas R Bailey

Jasbir Singh

Lars J S Knutsen

Gregory R Ott

Eugen F Mesaros

Chikara Murakata

Henry Joseph Breslin

Benjamin J Dugan

Melody McWherter

Bruce A Ruggeri

Emma L Morris

Christelle N Soudy

Katherine M Fowler

Nathaniel J T Monck

Ted Underiner

Gregoire A Pave

Ikeoluwa Olowoye

Mart Saarma

Keith S Learn

Gregory J Wells

Peter D Brown

David B Whitman

Mark A Ator

Jason C Wagner

Jonathan R A Roffey

Kevin J Wells-Knecht

Reddeppareddy Dandu

Jukka Ylikoski

Ulla Pirvola

Kevin M Walton

Masami Hamano

Tao Guo

Matthew S Miller

Ron H Bihovsky

Karen L Milkiewicz

Chia-Yu Huang

Nicola T Neff

Brigitte Lesur

Joseph Lisko

Jay P Theroff

Marcie A Glicksman

Christophe Yue

Tho V Thieu

Reiko Tanaka

Jonathan R Roffey

Minglang Wu

Lisa Guise-Zawacki

Rieko Tanaka

Lisa D Aimone

David P Rotella

Thelma S Angeles

Mangeng M Cheng

Rachael Hunter

Neil W Johnson

Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.

Spiropiperidine derivatives

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

Substituted 4-benzyl and 4-benzoyl piperidine derivates

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

1,4-substituted piperidine derivatives

Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses. 

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. 

Substituted 4-benzyl and 4-benzoyl piperidine derivatives

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. 

The present application provides a compound of formula (I) and/or a salt thereof, wherein R, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.

Azaquinazoline inhibitors of atypical protein kinase C

This application describes the use of the compound (I) or a salt thereof, either alone or in combination with other therapeutically active agents, for the treatment of particular cancers, including any solid or hematological cancer in which AXL or c-Met is over-expressed. 

Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents

The present invention provides compounds of Formula I or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, D, W, R, R, R, Y, R, X, E and G are as defined herein, methods of treatment and uses thereof.

Uracil derivatives as AXL and c-MET kinase inhibitors

The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C ('aPKC') inhibitory activity, and may be used to treat proliferative disorders.

Azaquinazoline inhibitors of Atypical protein Kinase C

The invention is directed to pyrazolo[1,5-a]pyridine derivatives and their use as AXL and c-MET kinase inhibitors.

Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Growing community of inventors

Chester Springs, PA, United States of America

Robert L Hudkins